Remote Oncology Clinical Development Lead

Sumitomo Pharma; Bismarck (ND); Remote; USD 226,000 - 282,000; Full time

Job summary

Sumitomo Pharma America seeks an Associate Medical Director, Clinical Development – Oncology. You will design and execute clinical studies, interact with investigators, and shape regulatory submissions.

This role emphasizes hematologic malignancies and requires leadership of cross-functional teams. MD/DO or non-US equivalent is required; residency strongly preferred, subspecialty fellowship desirable, and experience in blood cancers or solid tumors is a plus.

Qualifications

• MD/DO or non-US equivalent required or strongly preferred.
• Residency completion is strongly preferred.
• Subspecialty fellowship desirable for advanced training.
• Experience in blood cancers or solid tumors desirable.

Responsibilities

• Own design and execution of clinical protocols aligned with development plans.
• Provide medical input to regulatory documents, publications, and site interactions.
• Lead clinical study teams; monitor study integrity and safety/efficacy data.
• Present at scientific, medical, and regulatory meetings globally.
• Develop relationships with investigators, KOLs, and partners; support regulatory filings.

Skills

Hematological malignancies knowledge

Clinical trial design

Leadership

Communication skills

Cross-functional collaboration

Regulatory understanding

Education

MD/DO or non-US equivalent

Residency completed

Subspecialty fellowship desirable

Experience in blood cancers or solid tumors desirable

Job description

Sumitomo Pharma America seeks an Associate Medical Director, Clinical Development – Oncology. You will design and execute clinical studies, interact with investigators, and shape regulatory submissions.

This role emphasizes hematologic malignancies and requires leadership of cross-functional teams. MD/DO or non-US equivalent is required; residency strongly preferred, subspecialty fellowship desirable, and experience in blood cancers or solid tumors is a plus.